Table 2.

Changes in primary and secondary outcomes^a

Variable	Mean change from baseline (95% CI)		Between-group difference (95% CI)
	JX pill group (N = 70)	Control group (N = 71)	JX pill group vs control group	P valueb
GISc
Week 4	−5.5 (−4.8, −6.3)	−4.2 (−3.5, −4.9)	−1.3 (−2.4, −0.3)	0.013
Week 8	−6.7 (−5.9, −7.4)	−5.3 (−4.6, −6.1)	−1.3 (−2.4, −0.2)	0.016
HAMDd
Week 4	−4.9 (−4.2, −5.7)	−4.2 (−3.4, −4.9)	−0.7 (−1.8, −0.3)	0.093
Week 8	−6.0 (−5.2, −6.7)	−5.2 (−4.5, −5.9)	−0.7 (−1.7, −0.2)	0.174
HAMAe
Week 4	−3.9 (−3.2, −4.6)	−3.6 (−2.9, −4.3)	−0.3 (−1.3, −0.7)	0.446
Week 8	−4.8 (−4.0, −5.6)	−4.2 (−3.4, −4.9)	−0.6 (−1.7, −0.5)	0.431

CI, confidence interval; FD, functional dyspepsia; GIS, Gastrointestinal Symptom Score; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; JX, Jiawei Xiaoyao.

^aAll values are mean, with the 95% CIs.

^bP values were calculated based on a repeated-measures analysis of variance.

^cThe severity of FD symptoms is assessed by the GIS. Scores range from 0 to 40, with higher scores indicating more severe symptoms.

^dThe HAMD score separately evaluates the depression status of participants. Scores range from 0 to 54, with 0 equaling no depression.

^eThe HAMA score separately evaluates the anxiety status of participants. Scores range from 0 to 56, with 0 equaling no anxiety.